Annovis Bio, Inc., a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company\'s lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer\'s disease (AD), and Parkinson\'s disease. It is also developing ANVS-301, a compound in Phase 1 clinical trials to increase cognitive capability in later stages of AD and dementia; and ANVS-405, which is in preclinical study for protecting the brain after traumatic brain injury and\u002For stroke. Annovis Bio, Inc. was formerly known as QR Pharma, Inc. and changed its name to Annovis Bio, Inc. in March 2019. The company was founded in 2008 and is based in Berwyn, Pennsylvania. The company trades on NYSE exchange. The company headquarter is located in Berwyn, PA. The company was established in the 2008.

TickerANVS
Long NameAnnovis Bio, Inc.
Short NameAnnovis Bio